In this study, we detected the mRNA and protein expression of OSBPL3 and Ki-67 in 92 CRC tissues and cancer-adjacent normal tissues by immunohistochemistry and qPCR and detected RAS gene mutation by the amplification refractory mutation system (ARMS) method to initially explore the role of OSBPL3 and the RAS signaling pathway in CRC progression and provide a theoretical basis for therapeutic target screening. This evidence concerns the gene OSBPL3 and cancer.